None, D. K. K. S., None, D. D. S. & None, D. R. A. (2026). Comparison of Dexmedetomidine and Esmolol for Controlled Hypotension and Surgical-Field Quality During Functional Endoscopic Sinus Surgery (FESS). Journal of Contemporary Clinical Practice, 12(11), 375-388.
MLA
None, Dr. Kapil Kumar Sidana, Dr. Deepika Sidana and Dr. Rakesh Aseri . "Comparison of Dexmedetomidine and Esmolol for Controlled Hypotension and Surgical-Field Quality During Functional Endoscopic Sinus Surgery (FESS)." Journal of Contemporary Clinical Practice 12.11 (2026): 375-388.
Chicago
None, Dr. Kapil Kumar Sidana, Dr. Deepika Sidana and Dr. Rakesh Aseri . "Comparison of Dexmedetomidine and Esmolol for Controlled Hypotension and Surgical-Field Quality During Functional Endoscopic Sinus Surgery (FESS)." Journal of Contemporary Clinical Practice 12, no. 11 (2026): 375-388.
Harvard
None, D. K. K. S., None, D. D. S. and None, D. R. A. (2026) 'Comparison of Dexmedetomidine and Esmolol for Controlled Hypotension and Surgical-Field Quality During Functional Endoscopic Sinus Surgery (FESS)' Journal of Contemporary Clinical Practice 12(11), pp. 375-388.
Vancouver
Dr. Kapil Kumar Sidana DKKS, Dr. Deepika Sidana DDS, Dr. Rakesh Aseri DRA. Comparison of Dexmedetomidine and Esmolol for Controlled Hypotension and Surgical-Field Quality During Functional Endoscopic Sinus Surgery (FESS). Journal of Contemporary Clinical Practice. 2026 Nov;12(11):375-388.
Background: Controlled hypotension during functional endoscopic sinus surgery (FESS) is employed to minimize intraoperative bleeding and improve surgical-field visibility. Dexmedetomidine and esmolol are commonly used agents with distinct haemodynamic effects and postoperative recovery profiles. The objective of this comparative study was to evaluate their effects on surgical-field quality, intraoperative haemodynamics, blood loss, surgical duration, postoperative analgesia, recovery characteristics, and perioperative adverse events.Materials and Methods: A comparative study framework was developed involving 100 patients aged 18–60 years with American Society of Anesthesiologists (ASA) physical status I–II undergoing elective FESS under general anaesthesia. The analysis included two equal groups: Group D (dexmedetomidine; n = 50) and Group E (esmolol; n = 50). The target mean arterial pressure (MAP) was 60–70 mmHg. Surgical-field quality was assessed using the Fromme–Boezaart grading scale. Intraoperative haemodynamic parameters, estimated blood loss, surgical duration, postoperative pain, recovery characteristics, analgesic requirements, and perioperative adverse events were compared.Results: In the comparative dataset, baseline demographic and haemodynamic characteristics were comparable between the groups. Favourable surgical-field visibility (Fromme–Boezaart Grades 0–2) was observed in 86.0% of Group D compared with 68.0% of Group E (p = 0.032). Mean surgical-field scores were 1.46 ± 0.97 and 2.06 ± 1.00, respectively (p = 0.003). Mean intraoperative blood loss was lower in Group D (112.6 ± 28.4 versus 139.8 ± 34.6 mL; p < 0.001), as was surgical duration (78.4 ± 15.6 versus 86.2 ± 17.3 minutes; p = 0.020). Mean intraoperative MAP was 66.8 ± 4.6 versus 70.4 ± 5.2 mmHg (p < 0.001), while mean heart rate was 69.8 ± 6.4 versus 74.6 ± 6.8 beats/min (p < 0.001). Rescue analgesia was required in 28.0% and 54.0% of patients, respectively (p = 0.008). However, extubation time was longer in Group D (11.6 ± 3.1 versus 8.4 ± 2.5 minutes; p < 0.001), as was post-anaesthesia care unit stay (52.4 ± 12.6 versus 46.8 ± 11.4 minutes; p = 0.022). No statistically significant differences were identified in individual perioperative adverse events.Conclusion: The comparative findings suggest that dexmedetomidine may provide better surgical-field visibility, reduced intraoperative blood loss, shorter surgical duration, and lower postoperative analgesic requirements than esmolol during FESS, although postoperative emergence and recovery may be slower.
Keywords
Dexmedetomidine
Esmolol
Controlled hypotension
Functional endoscopic sinus surgery
Surgical-field quality
Intraoperative blood loss
Haemodynamic stability.
INTRODUCTION
Functional endoscopic sinus surgery (FESS) is a minimally invasive procedure commonly performed for chronic rhinosinusitis and other sinonasal disorders. Adequate surgical-field visibility is essential for precise dissection and prevention of injury to critical structures, particularly the orbit and skull base. However, the rich vascularity of the sinonasal mucosa and confined operative space make intraoperative bleeding a significant challenge. Even minor bleeding may obscure anatomical landmarks, necessitate frequent suctioning, and prolong surgery. Therefore, minimizing blood loss while maintaining adequate organ perfusion is an important objective of anaesthetic management during FESS [1–3].
Controlled hypotension is an established anaesthetic technique involving deliberate reduction of arterial blood pressure to a predefined target to minimize bleeding and improve surgical visibility. Various agents, including beta-adrenergic blockers, alpha-2 adrenergic agonists, and vasodilators, have been employed for this purpose. An ideal hypotensive agent should provide predictable haemodynamic control, satisfactory surgical conditions, rapid postoperative recovery, and minimal adverse effects without compromising vital organ perfusion [1–3].
Dexmedetomidine is a highly selective alpha-2 adrenergic receptor agonist with sedative, analgesic, and sympatholytic properties. By reducing central sympathetic outflow, it decreases heart rate and arterial blood pressure while attenuating haemodynamic responses to surgical stimulation. Its analgesic-sparing effects offer additional perioperative benefits; however, bradycardia, hypotension, and delayed postoperative recovery remain potential concerns [1,3,4].
Esmolol is an ultra-short-acting, relatively selective beta-1 adrenergic receptor antagonist that reduces heart rate, myocardial contractility, and cardiac output. Its rapid onset, short elimination half-life, and ease of titration make it suitable for controlled hypotension. Unlike dexmedetomidine, esmolol lacks intrinsic sedative properties and may facilitate earlier postoperative emergence. Nevertheless, excessive beta-blockade may cause bradycardia, hypotension, and reduced cardiac output [1–3,5].
Previous studies have demonstrated the effectiveness of both agents during FESS. Shams et al. [1] compared dexmedetomidine and esmolol for induced hypotension, while Bajwa et al. [2] evaluated these agents alongside nitroglycerine. Sahu et al. [3] further investigated their comparative haemodynamic effects, whereas Omara et al. [4] examined postoperative analgesia and recovery outcomes. Srivastava et al. [5] also demonstrated the utility of esmolol compared with nitroglycerine. Despite these investigations, differences in surgical-field quality, haemodynamic stability, blood loss, postoperative analgesia, and recovery characteristics warrant further evaluation.
The present study was designed to compare dexmedetomidine and esmolol for controlled hypotension during FESS under general anaesthesia at Dr. S.S. Tantia Medical College, Sri Ganganagar, Rajasthan, India. The primary objective was to compare intraoperative surgical-field quality using the Fromme–Boezaart grading scale. The secondary objectives were to evaluate intraoperative haemodynamic parameters, estimated blood loss, surgical duration, postoperative recovery, analgesic requirements, and perioperative adverse events.
MATERIALS AND METHODS
Study Design and Setting
The study was conducted at the Department of Anaesthesiology in collaboration with the Department of Otorhinolaryngology, Dr. S.S. Tantia Medical College, Sri Ganganagar, Rajasthan, India, over a period of 12 months, from July 2025 to June 2026. It was designed as a single-centre comparative clinical study to evaluate the efficacy and safety of dexmedetomidine and esmolol for controlled hypotension during functional endoscopic sinus surgery (FESS) under general anaesthesia.
Study Population and Sample Size
The study was designed to compare 100 adult patients aged 18–60 years, of either sex, with American Society of Anesthesiologists (ASA) physical status I or II, undergoing elective FESS under general anaesthesia. The two comparison groups were defined as Group D (dexmedetomidine; n = 50) and Group E (esmolol; n = 50).
Inclusion and Exclusion Criteria
Patients aged 18–60 years, of either sex, belonging to ASA physical status I or II and scheduled for elective FESS under general anaesthesia were eligible for inclusion.
Patients with uncontrolled hypertension, significant cardiovascular disease, cardiac conduction abnormalities, resting bradycardia, severe hepatic or renal impairment, coagulation disorders, pregnancy, known hypersensitivity to either study medication, or contraindications to controlled hypotension were excluded. Patients receiving medications likely to interfere with haemodynamic responses were also excluded.
Preoperative Assessment
Preoperative assessment included detailed medical history, general physical examination, systemic examination, airway assessment, and relevant laboratory investigations. Demographic and clinical characteristics, including age, sex, body weight, and ASA physical status, were recorded. Baseline haemodynamic parameters, including heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), and peripheral oxygen saturation (SpO₂), were documented before induction of anaesthesia.
Anaesthetic Technique and Drug Administration
Standard intraoperative monitoring included electrocardiography, non-invasive blood pressure measurement, pulse oximetry, and capnography. Intravenous access was secured, and general anaesthesia was administered according to the institutional anaesthetic protocol.
The study drug regimens were specified as follows:
• Group D (Dexmedetomidine): An intravenous loading dose of 1 µg/kg administered over 10 minutes, followed by a maintenance infusion of 0.5 µg/kg/hour.
• Group E (Esmolol): An intravenous loading dose of 1 mg/kg administered over 1 minute, followed by a maintenance infusion of 0.5 mg/kg/hour.
Controlled hypotension was targeted at a MAP of 60–70 mmHg, with adjustments according to individual haemodynamic responses and patient safety requirements. Drug infusion rates were titrated to achieve the desired MAP. Episodes of excessive hypotension, bradycardia, or other haemodynamic disturbances were managed according to the institutional anaesthesia protocol.
Intraoperative Haemodynamic Monitoring
Intraoperative haemodynamic parameters, including HR, SBP, DBP, and MAP, were recorded at baseline, after induction of anaesthesia, immediately following endotracheal intubation, and at 5, 10, 15, 20, 25, 30, 45, and 60 minutes, as well as at the end of surgery.
The haemodynamic assessment included achievement of target MAP, time required to achieve the target MAP, and requirements for additional hypotensive medication. Episodes of bradycardia, hypotension, tachycardia, and other haemodynamic disturbances, along with corrective pharmacological interventions, were documented.
Assessment of Surgical-Field Quality
Surgical-field quality was assessed using the six-point Fromme–Boezaart grading scale, ranging from Grade 0 (no bleeding) to Grade 5 (severe bleeding substantially interfering with surgery). Lower scores indicated better surgical-field visibility.
The assessment protocol specified surgical-field grading at 15-minute intervals during the procedure. Grades 0–2 were categorized as favourable surgical-field visibility, whereas Grades 3–5 indicated poorer visibility.
Assessment of Intraoperative Blood Loss and Surgical Duration
Intraoperative blood loss was estimated by subtracting the volume of irrigation fluid from the total fluid collected in the suction canister. Blood retained in surgical packs or gauze was additionally considered when quantified. Estimated blood loss was expressed in millilitres (mL).
Surgical duration was calculated from the commencement to the completion of the operative procedure and recorded in minutes.
Postoperative Assessment
Following completion of surgery, study drug infusions were discontinued, and postoperative recovery was assessed according to the institutional protocol. Recovery parameters included time to eye opening, time to extubation, and duration of stay in the post-anaesthesia care unit (PACU).
Postoperative pain intensity was assessed using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain), at 30 minutes, 1 hour, and 2 hours after surgery. Rescue analgesic requirements and time to first rescue analgesic administration were documented.
Perioperative adverse events included bradycardia, hypotension, tachycardia, hypertension during emergence, postoperative nausea and vomiting, and excessive postoperative sedation. Requirements for atropine administration and vasopressor support were also evaluated.
Outcome Measures
The primary outcome was intraoperative surgical-field quality assessed using the Fromme–Boezaart grading scale.
Secondary outcomes included intraoperative HR, SBP, DBP, and MAP; achievement of target MAP; time to achieve the target MAP; estimated intraoperative blood loss; surgical duration; postoperative recovery characteristics; postoperative pain scores; rescue analgesic requirements; and perioperative adverse events.
Statistical Analysis
Data was entered in Microsoft Excel and analysed using IBM SPSS Statistics, version 26.0. Continuous variables were summarized as mean ± standard deviation (SD) or median with interquartile range, according to their distribution, while categorical variables were expressed as frequencies and percentages.
Normality of continuous variables was assessed using the Shapiro–Wilk test. Between-group comparisons were specified using the independent-samples Student's t-test for approximately normally distributed continuous variables and the Mann–Whitney U test for non-normally distributed or ordinal variables, as appropriate. Categorical variables were compared using Pearson's chi-square test or Fisher's exact test, depending on expected cell frequencies.
For repeated intraoperative haemodynamic measurements, the analysis plan specified a linear mixed-effects model incorporating treatment group, time, and their interaction as fixed effects, with a patient-level random intercept to account for within-subject correlation. Statistical significance was defined as a two-sided p-value of less than 0.05, with 95% confidence intervals.
RESULTS
Baseline Demographic and Clinical Characteristics
Table 1 presents the baseline demographic and clinical characteristics of the two comparison groups. The mean age was 36.8 ± 10.4 years in Group D and 37.6 ± 9.8 years in Group E (p = 0.693). Male participants accounted for 58.0% and 62.0% of the respective groups. The mean body weight was 65.4 ± 9.2 kg in Group D and 66.1 ± 8.8 kg in Group E (p = 0.698). ASA physical status I was recorded in 68.0% of Group D and 64.0% of Group E. The reported comparisons showed no statistically significant differences in baseline demographic or clinical characteristics between the groups.
Table 1. Comparison of baseline demographic and clinical characteristics between the two study groups (N = 100)
Characteristics Group D (n = 50) Group E (n = 50) p-value
Age (years), mean ± SD 36.8 ± 10.4 37.6 ± 9.8 0.693
Male, n (%) 29 (58.0) 31 (62.0) 0.683
Female, n (%) 21 (42.0) 19 (38.0) —
Body weight (kg), mean ± SD 65.4 ± 9.2 66.1 ± 8.8 0.698
ASA physical status I, n (%) 34 (68.0) 32 (64.0) 0.673
ASA physical status II, n (%) 16 (32.0) 18 (36.0) —
Baseline HR (beats/min), mean ± SD 83.6 ± 8.4 84.2 ± 8.1 0.717
Baseline SBP (mmHg), mean ± SD 124.8 ± 9.6 125.6 ± 9.2 0.671
Baseline DBP (mmHg), mean ± SD 79.4 ± 6.8 80.1 ± 6.5 0.600
Baseline MAP (mmHg), mean ± SD 94.5 ± 7.2 95.3 ± 6.9 0.572
Group D: dexmedetomidine; Group E: esmolol; ASA: American Society of Anesthesiologists; HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; SD: standard deviation.
Baseline Haemodynamic Parameters
Baseline haemodynamic parameters were comparable between the two groups in the supplied summary data. Mean heart rate was 83.6 ± 8.4 beats/min in Group D and 84.2 ± 8.1 beats/min in Group E (p = 0.717). Mean systolic blood pressure was 124.8 ± 9.6 mmHg and 125.6 ± 9.2 mmHg, respectively (p = 0.671), while mean diastolic blood pressure was 79.4 ± 6.8 mmHg and 80.1 ± 6.5 mmHg (p = 0.600). Mean arterial pressure was 94.5 ± 7.2 mmHg in Group D compared with 95.3 ± 6.9 mmHg in Group E (p = 0.572). None of the reported baseline haemodynamic comparisons reached statistical significance.
Table 2. Comparison of intraoperative heart rate at different time intervals between dexmedetomidine and esmolol groups (N = 100)
Time interval Group D (n = 50) Mean ± SD Group E (n = 50) Mean ± SD p-value
Baseline 83.6 ± 8.4 84.2 ± 8.1 0.717
After induction 78.4 ± 7.6 80.1 ± 7.9 0.276
Immediately after intubation 85.2 ± 8.3 88.6 ± 8.7 0.048
5 minutes 75.6 ± 7.2 79.4 ± 7.6 0.012
10 minutes 71.8 ± 6.8 76.3 ± 7.1 0.002
15 minutes 69.4 ± 6.5 74.8 ± 6.9 <0.001
20 minutes 68.2 ± 6.3 73.6 ± 6.7 <0.001
25 minutes 67.6 ± 6.1 72.9 ± 6.5 <0.001
30 minutes 67.2 ± 6.2 72.4 ± 6.4 <0.001
45 minutes 68.1 ± 6.4 73.2 ± 6.6 <0.001
60 minutes 69.3 ± 6.7 74.1 ± 6.8 <0.001
End of surgery 72.6 ± 7.1 76.8 ± 7.4 0.005
Group D: dexmedetomidine; Group E: esmolol; SD: standard deviation. Heart rate is expressed in beats/minute.
The study showed comparable baseline mean heart rates in Group D (83.6 ± 8.4 beats/min) and Group E (84.2 ± 8.1 beats/min; p = 0.717). Following induction of anaesthesia, heart rate decreased in both groups, followed by a transient increase immediately after endotracheal intubation. The mean heart rate immediately after intubation was lower in Group D (85.2 ± 8.3 beats/min) than in Group E (88.6 ± 8.7 beats/min; reported p = 0.048). During the subsequent intraoperative period, mean heart rates were consistently lower in the dexmedetomidine group. At 15 minutes, the mean heart rate was 69.4 ± 6.5 beats/min in Group D compared with 74.8 ± 6.9 beats/min in Group E (reported p < 0.001). The lowest group mean heart rates were observed at 30 minutes, measuring 67.2 ± 6.2 and 72.4 ± 6.4 beats/min, respectively. Thereafter, mean heart rates gradually increased in both groups but remained lower in Group D at the end of surgery (72.6 ± 7.1 versus 76.8 ± 7.4 beats/min; reported p = 0.005). Overall, the study results indicated a greater reduction in mean intraoperative heart rate in the dexmedetomidine group than in the esmolol group.
Table 3. Comparison of intraoperative mean arterial pressure at different time intervals between dexmedetomidine and esmolol groups (N = 100)
Time interval Group D (n = 50) Mean ± SD Group E (n = 50) Mean ± SD p-value
Baseline 94.5 ± 7.2 95.3 ± 6.9 0.572
After induction 84.2 ± 6.8 86.1 ± 7.1 0.175
Immediately after intubation 91.6 ± 7.5 94.8 ± 7.8 0.039
5 minutes 77.4 ± 6.3 80.2 ± 6.7 0.034
10 minutes 71.6 ± 5.8 75.3 ± 6.1 0.003
15 minutes 67.8 ± 5.2 71.9 ± 5.7 <0.001
20 minutes 65.9 ± 4.8 69.8 ± 5.2 <0.001
25 minutes 65.1 ± 4.6 68.7 ± 4.9 <0.001
30 minutes 64.8 ± 4.5 68.2 ± 4.7 <0.001
45 minutes 65.4 ± 4.7 68.9 ± 4.8 <0.001
60 minutes 66.2 ± 4.9 69.6 ± 5.1 0.001
End of surgery 72.8 ± 5.8 76.1 ± 6.2 0.007
Group D: dexmedetomidine; Group E: esmolol; MAP: mean arterial pressure; SD: standard deviation. All MAP values are expressed in mmHg.
The results showed comparable baseline MAP in Group D (94.5 ± 7.2 mmHg) and Group E (95.3 ± 6.9 mmHg; p = 0.572). Following induction of anaesthesia, MAP decreased in both groups, followed by a transient increase immediately after endotracheal intubation. The mean MAP immediately after intubation was lower in Group D (91.6 ± 7.5 mmHg) than in Group E (94.8 ± 7.8 mmHg; reported p = 0.039). During the subsequent intraoperative period, MAP progressively decreased in both groups, with consistently lower mean values in the dexmedetomidine group. At 15 minutes, mean MAP was 67.8 ± 5.2 mmHg in Group D compared with 71.9 ± 5.7 mmHg in Group E (reported p < 0.001). The lowest group mean MAP values were observed at 30 minutes, measuring 64.8 ± 4.5 mmHg and 68.2 ± 4.7 mmHg, respectively. Thereafter, MAP remained relatively stable before gradually increasing toward the end of surgery. At surgical completion, mean MAP was 72.8 ± 5.8 mmHg in Group D and 76.1 ± 6.2 mmHg in Group E (reported p = 0.007). Overall, the study indicated lower mean intraoperative MAP in the dexmedetomidine group than in the esmolol group during the measured operative intervals.
Table 4. Comparison of intraoperative systolic and diastolic blood pressure between dexmedetomidine and esmolol groups (N = 100)
Time interval Group D SBP (Mean ± SD) Group E SBP (Mean ± SD) p-value Group D DBP (Mean ± SD) Group E DBP (Mean ± SD) p-value
Baseline 124.8 ± 9.6 125.6 ± 9.2 0.671 79.4 ± 6.8 80.1 ± 6.5 0.600
After induction 112.4 ± 8.8 114.6 ± 9.1 0.222 70.1 ± 6.4 71.8 ± 6.7 0.198
Immediately after intubation 122.6 ± 9.4 126.8 ± 9.8 0.031 76.1 ± 6.9 78.8 ± 7.2 0.058
5 minutes 104.8 ± 8.2 108.6 ± 8.6 0.026 63.7 ± 5.9 66.0 ± 6.1 0.058
10 minutes 97.6 ± 7.8 102.4 ± 8.1 0.003 58.6 ± 5.5 61.8 ± 5.8 0.006
15 minutes 92.4 ± 7.2 97.8 ± 7.6 <0.001 55.5 ± 5.1 59.0 ± 5.4 0.001
20 minutes 90.1 ± 6.9 95.4 ± 7.1 <0.001 53.8 ± 4.8 57.0 ± 5.0 0.002
25 minutes 89.2 ± 6.7 94.3 ± 6.9 <0.001 53.1 ± 4.6 56.0 ± 4.8 0.003
30 minutes 88.8 ± 6.6 93.6 ± 6.8 <0.001 52.8 ± 4.5 55.5 ± 4.7 0.004
45 minutes 89.6 ± 6.8 94.5 ± 7.0 <0.001 53.3 ± 4.7 56.1 ± 4.9 0.005
60 minutes 90.8 ± 7.1 95.6 ± 7.3 0.001 53.9 ± 4.9 56.6 ± 5.1 0.008
End of surgery 99.2 ± 8.0 103.8 ± 8.3 0.006 59.6 ± 5.6 62.2 ± 5.9 0.026
Group D: dexmedetomidine (n = 50); Group E: esmolol (n = 50); SBP: systolic blood pressure; DBP: diastolic blood pressure; SD: standard deviation. All blood pressure values are expressed in mmHg.
Table 4 presents the intraoperative changes in systolic and diastolic blood pressure in the dexmedetomidine and esmolol groups. Baseline systolic blood pressure (SBP) was comparable between Group D (124.8 ± 9.6 mmHg) and Group E (125.6 ± 9.2 mmHg; p = 0.671). Similarly, baseline diastolic blood pressure (DBP) was 79.4 ± 6.8 mmHg and 80.1 ± 6.5 mmHg, respectively (p = 0.600). Following induction of anaesthesia, both SBP and DBP decreased in the two groups, followed by a transient increase immediately after endotracheal intubation. The mean SBP immediately after intubation was lower in Group D (122.6 ± 9.4 mmHg) than in Group E (126.8 ± 9.8 mmHg; reported p = 0.031), whereas the corresponding difference in DBP did not reach statistical significance (p = 0.058). During the subsequent intraoperative period, both SBP and DBP progressively decreased, with consistently lower mean values in the dexmedetomidine group. At 15 minutes, mean SBP was 92.4 ± 7.2 mmHg in Group D compared with 97.8 ± 7.6 mmHg in Group E (reported p < 0.001), while the corresponding DBP values were 55.5 ± 5.1 mmHg and 59.0 ± 5.4 mmHg, respectively (reported p = 0.001). The lowest group mean blood pressure values were observed at 30 minutes, with SBP of 88.8 ± 6.6 mmHg and DBP of 52.8 ± 4.5 mmHg in Group D, compared with SBP of 93.6 ± 6.8 mmHg and DBP of 55.5 ± 4.7 mmHg in Group E. Thereafter, both SBP and DBP increased gradually toward the end of surgery. At surgical completion, mean SBP remained lower in Group D (99.2 ± 8.0 mmHg) than in Group E (103.8 ± 8.3 mmHg; reported p = 0.006). Corresponding DBP values were 59.6 ± 5.6 mmHg and 62.2 ± 5.9 mmHg, respectively (reported p = 0.026). Overall, the study results indicated lower intraoperative systolic and diastolic blood pressure in the dexmedetomidine group during most of the measured operative intervals.
Table 5. Comparison of intraoperative surgical-field quality using the Fromme–Boezaart grading scale between dexmedetomidine and esmolol groups (N = 100)
Surgical-field quality Group D (n = 50) Group E (n = 50) p-value
Grade 0 – No bleeding 8 (16.0%) 3 (6.0%) —
Grade 1 – Slight bleeding, no suctioning required 19 (38.0%) 11 (22.0%) —
Grade 2 – Slight bleeding, occasional suctioning 16 (32.0%) 20 (40.0%) —
Grade 3 – Frequent suctioning required 6 (12.0%) 12 (24.0%) —
Grade 4 – Moderate bleeding, field immediately obscured 1 (2.0%) 4 (8.0%) —
Grade 5 – Severe bleeding 0 (0.0%) 0 (0.0%) —
Total 50 (100%) 50 (100%) —
Grades 0–2 (better surgical visibility) 43 (86.0%) 34 (68.0%) 0.032
Grades 3–5 (poorer surgical visibility) 7 (14.0%) 16 (32.0%) —
Reported mean surgical-field score ± SD 1.46 ± 0.97 2.06 ± 1.00 0.003
Group D: dexmedetomidine; Group E: esmolol; SD: standard deviation. Lower Fromme–Boezaart grades indicate better surgical-field visibility.
Table 5 presents the distribution of intraoperative surgical-field quality grades in the dexmedetomidine and esmolol groups using the Fromme–Boezaart grading scale. Grade 0 (no bleeding) was recorded in 8 patients (16.0%) in Group D compared with 3 patients (6.0%) in Group E. Grade 1 was recorded in 19 patients (38.0%) and 11 patients (22.0%), respectively, whereas Grade 2 was recorded in 16 patients (32.0%) in Group D and 20 patients (40.0%) in Group E. Higher grades, indicating greater bleeding and increased suctioning requirements, were more frequent in the esmolol group. Favourable surgical-field visibility (Grades 0–2) was recorded in 43 patients (86.0%) in Group D compared with 34 patients (68.0%) in Group E (reported p = 0.032). Conversely, poorer surgical-field visibility (Grades 3–5) was recorded in 7 patients (14.0%) and 16 patients (32.0%), respectively. The study reported a lower mean surgical-field score in Group D (1.46 ± 0.97) than in Group E (2.06 ± 1.00; reported p = 0.003). These comparisons indicated a greater proportion of favourable surgical-field grades in the dexmedetomidine group.
Table 6. Comparison of intraoperative blood loss, surgical duration, and achievement of target mean arterial pressure between dexmedetomidine and esmolol groups (N = 100)
Intraoperative parameters Group D (n = 50) Group E (n = 50) Reported p-value
Estimated blood loss (mL), mean ± SD 112.6 ± 28.4 139.8 ± 34.6 <0.001
Duration of surgery (minutes), mean ± SD 78.4 ± 15.6 86.2 ± 17.3 0.020
Time to achieve target MAP (minutes), mean ± SD 12.8 ± 3.6 16.4 ± 4.2 <0.001
Patients achieving target MAP, n (%) 46 (92.0%) 42 (84.0%) 0.218
Patients requiring additional hypotensive medication, n (%) 4 (8.0%) 9 (18.0%) 0.137
Mean intraoperative MAP (mmHg), mean ± SD 66.8 ± 4.6 70.4 ± 5.2 <0.001
Mean intraoperative HR (beats/min), mean ± SD 69.8 ± 6.4 74.6 ± 6.8 <0.001
Group D: dexmedetomidine; Group E: esmolol; MAP: mean arterial pressure; HR: heart rate; SD: standard deviation.
Table 6 presents the comparison of intraoperative blood loss, surgical duration, and haemodynamic outcomes between the dexmedetomidine and esmolol groups. Mean estimated intraoperative blood loss was lower in Group D (112.6 ± 28.4 mL) than in Group E (139.8 ± 34.6 mL; reported p < 0.001). The mean duration of surgery was also shorter in Group D (78.4 ± 15.6 minutes) compared with Group E (86.2 ± 17.3 minutes; reported p = 0.020). The mean time required to achieve the target mean arterial pressure was 12.8 ± 3.6 minutes in Group D and 16.4 ± 4.2 minutes in Group E (reported p < 0.001). Target MAP was achieved in 46 patients (92.0%) in Group D compared with 42 patients (84.0%) in Group E (reported p = 0.218). Additional hypotensive medication was required in 4 patients (8.0%) receiving dexmedetomidine and 9 patients (18.0%) receiving esmolol (reported p = 0.137). Mean intraoperative MAP was lower in Group D (66.8 ± 4.6 mmHg) than in Group E (70.4 ± 5.2 mmHg; reported p < 0.001). Similarly, mean intraoperative heart rate was 69.8 ± 6.4 beats/min in Group D compared with 74.6 ± 6.8 beats/min in Group E (reported p < 0.001). Overall, the comparisons indicated lower estimated blood loss, shorter surgical duration, earlier achievement of target MAP, and lower mean intraoperative MAP and heart rate in the dexmedetomidine group. However, the reported differences in the proportions achieving target MAP and requiring additional hypotensive medication did not reach statistical significance.
Table 7. Comparison of postoperative recovery characteristics, pain scores, and analgesic requirements between dexmedetomidine and esmolol groups (N = 100)
Postoperative parameters Group D (n = 50) Group E (n = 50) Reported p-value
Time to eye opening (minutes), mean ± SD 9.8 ± 2.6 7.2 ± 2.1 <0.001
Time to extubation (minutes), mean ± SD 11.6 ± 3.1 8.4 ± 2.5 <0.001
Pain score at 30 minutes, mean ± SD 2.4 ± 0.9 3.6 ± 1.1 <0.001
Pain score at 1 hour, mean ± SD 2.7 ± 1.0 3.8 ± 1.2 <0.001
Pain score at 2 hours, mean ± SD 2.3 ± 0.9 3.2 ± 1.1 <0.001
Time to first rescue analgesia (minutes), mean ± SD 148.6 ± 34.2 112.4 ± 29.6 <0.001
Patients requiring rescue analgesia, n (%) 14 (28.0%) 27 (54.0%) 0.008
Duration of PACU stay (minutes), mean ± SD 52.4 ± 12.6 46.8 ± 11.4 0.022
Group D: dexmedetomidine; Group E: esmolol; SD: standard deviation; PACU: post-anaesthesia care unit. Pain scores were assumed to use an 11-point numerical rating scale (0–10).
Table 7 presents the postoperative recovery characteristics, pain scores, and analgesic requirements in the dexmedetomidine and esmolol groups. Mean time to eye opening was longer in Group D (9.8 ± 2.6 minutes) than in Group E (7.2 ± 2.1 minutes; reported p < 0.001). Similarly, mean time to extubation was 11.6 ± 3.1 minutes in Group D compared with 8.4 ± 2.5 minutes in Group E (reported p < 0.001). Postoperative pain scores were consistently lower in the dexmedetomidine group at all three assessment intervals. At 30 minutes, mean pain scores were 2.4 ± 0.9 in Group D and 3.6 ± 1.1 in Group E (reported p < 0.001). At 1 hour, the corresponding scores were 2.7 ± 1.0 and 3.8 ± 1.2, respectively, while at 2 hours they were 2.3 ± 0.9 and 3.2 ± 1.1, respectively, with reported p-values < 0.001 at both intervals. The mean time to first rescue analgesia was longer in Group D (148.6 ± 34.2 minutes) than in Group E (112.4 ± 29.6 minutes; reported p < 0.001). Rescue analgesia was required in 14 patients (28.0%) in Group D compared with 27 patients (54.0%) in Group E (reported p = 0.008). The mean duration of stay in the post-anaesthesia care unit was longer in Group D (52.4 ± 12.6 minutes) than in Group E (46.8 ± 11.4 minutes; reported p = 0.022). Overall, the comparisons indicated lower postoperative pain scores and fewer rescue analgesic requirements in the dexmedetomidine group, accompanied by longer times to eye opening, extubation, and PACU discharge.
Table 8. Comparison of perioperative adverse events and safety outcomes between dexmedetomidine and esmolol groups (N = 100)
Adverse events Group D (n = 50), n (%) Group E (n = 50), n (%) Reported p-value
Bradycardia 6 (12.0) 3 (6.0) 0.487
Hypotension below target MAP 5 (10.0) 3 (6.0) 0.715
Hypertension during emergence 2 (4.0) 5 (10.0) 0.436
Tachycardia 2 (4.0) 6 (12.0) 0.269
Postoperative nausea 5 (10.0) 8 (16.0) 0.554
Postoperative vomiting 2 (4.0) 4 (8.0) 0.678
Excessive postoperative sedation 6 (12.0) 2 (4.0) 0.269
Requirement for atropine 3 (6.0) 1 (2.0) 0.617
Requirement for vasopressor support 2 (4.0) 1 (2.0) 1.000
Serious perioperative adverse events 0 (0.0) 0 (0.0) —
Group D: dexmedetomidine; Group E: esmolol; MAP: mean arterial pressure.
Table 8 presents the distribution of perioperative adverse events and safety outcomes in the dexmedetomidine and esmolol groups. Bradycardia was recorded in 6 patients (12.0%) in Group D compared with 3 patients (6.0%) in Group E (reported p = 0.487). Hypotension below the target mean arterial pressure was recorded in 5 patients (10.0%) and 3 patients (6.0%), respectively (reported p = 0.715). Hypertension during emergence was less frequent in Group D than in Group E (4.0% versus 10.0%; reported p = 0.436). Similarly, tachycardia was recorded in 2 patients (4.0%) receiving dexmedetomidine compared with 6 patients (12.0%) receiving esmolol (reported p = 0.269). Postoperative nausea occurred in 5 patients (10.0%) in Group D and 8 patients (16.0%) in Group E (reported p = 0.554), whereas postoperative vomiting occurred in 2 patients (4.0%) and 4 patients (8.0%), respectively (reported p = 0.678). Excessive postoperative sedation was recorded in 6 patients (12.0%) in Group D compared with 2 patients (4.0%) in Group E (reported p = 0.269). Atropine administration was required in 3 patients (6.0%) receiving dexmedetomidine and 1 patient (2.0%) receiving esmolol (reported p = 0.617). Vasopressor support was required in 2 patients (4.0%) and 1 patient (2.0%), respectively (reported p = 1.000). No serious perioperative adverse events were included in either group. None of the reported individual comparisons reached statistical significance. Nevertheless, the numerical differences suggested varying adverse-event profiles between the two agents, with more bradycardia and excessive postoperative sedation in the dexmedetomidine group and more tachycardia and emergence hypertension in the esmolol group.
DISCUSSION
Controlled hypotension is an important component of anaesthetic management during functional endoscopic sinus surgery (FESS), as intraoperative bleeding can obscure anatomical landmarks, compromise surgical precision, and prolong operative duration. An ideal hypotensive agent should provide effective haemodynamic control, improve surgical-field visibility, minimize blood loss, and facilitate postoperative recovery without compromising patient safety. Dexmedetomidine and esmolol are widely used for this purpose because of their distinct pharmacological mechanisms and favourable haemodynamic effects. Previous studies have demonstrated their effectiveness during FESS, although their relative advantages vary across clinical outcomes [1–5]. The present comparison examined the effects of these agents on surgical-field quality, intraoperative haemodynamics, blood loss, surgical duration, postoperative analgesia, recovery characteristics, and perioperative adverse events.
Baseline Characteristics and Comparability
The comparative analysis included 100 patients, with 50 patients in each treatment group. Baseline demographic and clinical characteristics, including age, sex distribution, body weight, American Society of Anesthesiologists (ASA) physical status, and haemodynamic parameters, were comparable between the dexmedetomidine and esmolol groups. Such comparability is important because differences in baseline cardiovascular status and physiological characteristics may influence responses to hypotensive agents. Shams et al. [1] and Sahu et al. [3] also evaluated baseline characteristics in their comparative studies of dexmedetomidine and esmolol during FESS. The similarity in baseline characteristics supports the comparability of the treatment groups, although it does not independently exclude potential confounding.
Intraoperative Heart Rate and Haemodynamic Response
Dexmedetomidine was associated with a greater reduction in intraoperative heart rate than esmolol, with consistently lower mean values during most operative intervals. At 30 minutes, mean heart rate was 67.2 ± 6.2 beats/min in the dexmedetomidine group compared with 72.4 ± 6.4 beats/min in the esmolol group (p < 0.001). The increase in heart rate following endotracheal intubation was also less pronounced with dexmedetomidine, indicating greater attenuation of the sympathetic response to airway manipulation.
These findings are consistent with the pharmacological properties of both agents. Dexmedetomidine, a highly selective alpha-2 adrenergic receptor agonist, reduces central sympathetic outflow and provides sedative and analgesic effects, whereas esmolol, an ultra-short-acting beta-1 adrenergic blocker, primarily reduces heart rate and myocardial contractility. Shams et al. [1] and Sahu et al. [3] investigated the haemodynamic effectiveness of these agents during FESS, while Bafna et al. [6] demonstrated favourable haemodynamic control with dexmedetomidine compared with clonidine. Variations in drug dosage, infusion regimens, background anaesthesia, and patient characteristics may explain differences in haemodynamic responses across studies.
Mean Arterial Pressure and Controlled Hypotension
Mean arterial pressure (MAP) decreased progressively following induction of anaesthesia in both groups, with lower mean values in the dexmedetomidine group during most intraoperative assessment intervals. At 30 minutes, mean MAP was 64.8 ± 4.5 mmHg in Group D compared with 68.2 ± 4.7 mmHg in Group E (p < 0.001). Both group means were within the predefined target MAP range of 60–70 mmHg, indicating that both agents were effective in achieving controlled hypotension.
Bajwa et al. [2] evaluated dexmedetomidine, esmolol, and nitroglycerine for induced hypotension during FESS, while Shams et al. [1] and Sahu et al. [3] compared the haemodynamic effects of dexmedetomidine and esmolol. These studies support the usefulness of both agents in maintaining controlled hypotension, although differences in drug administration, haemodynamic targets, and anaesthetic techniques may influence their comparative effectiveness.
Importantly, achieving a lower MAP should not be considered an advantage in isolation, as the primary objective of controlled hypotension is to improve surgical conditions while maintaining adequate tissue perfusion. Therefore, the effectiveness of an agent should be evaluated in relation to surgical-field visibility, haemodynamic stability, achievement of the desired MAP, and the occurrence of excessive hypotension.
Systolic and Diastolic Blood Pressure
Both systolic and diastolic blood pressure decreased following induction of anaesthesia, with lower mean values in the dexmedetomidine group throughout most of the operative period. The lowest mean values were observed at approximately 30 minutes, followed by a gradual increase towards the end of surgery. At 30 minutes, mean systolic blood pressure was 88.8 ± 6.6 mmHg in Group D compared with 93.6 ± 6.8 mmHg in Group E, while the corresponding diastolic blood pressure values were 52.8 ± 4.5 and 55.5 ± 4.7 mmHg, respectively.
These findings are consistent with the sympatholytic and hypotensive effects of dexmedetomidine. Gupta et al. [7] reported favourable haemodynamic control with dexmedetomidine compared with propofol during FESS, while Bafna et al. [6] demonstrated its effectiveness compared with clonidine. Although these investigations used different comparator agents, they provide supporting evidence for the role of dexmedetomidine in maintaining intraoperative haemodynamic control.
Surgical-Field Quality
Surgical-field quality was the primary outcome of the comparative analysis. Favourable surgical-field visibility, defined as Fromme–Boezaart Grades 0–2, was observed in 43 patients (86.0%) receiving dexmedetomidine compared with 34 patients (68.0%) receiving esmolol (p = 0.032). Mean surgical-field scores were also lower in the dexmedetomidine group (1.46 ± 0.97 versus 2.06 ± 1.00; p = 0.003), suggesting better operative visibility with dexmedetomidine.
Improved surgical-field visibility may be attributed to the sympatholytic effects of dexmedetomidine, which reduce arterial pressure and potentially minimize bleeding from the vascular sinonasal mucosa. Shams et al. [1] demonstrated the effectiveness of both dexmedetomidine and esmolol in providing satisfactory surgical conditions, while Bajwa et al. [2] also evaluated their effects on operative visibility. However, Escamilla et al. [8], comparing dexmedetomidine with clonidine, did not identify a significant difference in the proportion of patients with poorer surgical-field scores, indicating that the relative benefits of dexmedetomidine may vary according to the comparator agent and clinical setting.
Surgical-field quality is influenced by several factors beyond haemodynamic control, including disease severity, local vascularity, anatomical variations, surgical technique, and the extent of surgery. Nevertheless, improved surgical visibility remains an important outcome because it may facilitate precise dissection and reduce operative interruptions.
Intraoperative Blood Loss and Duration of Surgery
Mean intraoperative blood loss was significantly lower in the dexmedetomidine group than in the esmolol group (112.6 ± 28.4 versus 139.8 ± 34.6 mL; p < 0.001), representing an absolute difference of 27.2 mL. Mean surgical duration was also shorter with dexmedetomidine (78.4 ± 15.6 versus 86.2 ± 17.3 minutes; p = 0.020), corresponding to a difference of 7.8 minutes.
These findings suggest that improved haemodynamic control and surgical-field visibility with dexmedetomidine may contribute to reduced intraoperative bleeding and more efficient surgical dissection. Gupta et al. [7] reported lower intraoperative blood loss with dexmedetomidine compared with propofol, while Srivastava et al. [5] demonstrated the effectiveness of esmolol compared with nitroglycerine during FESS.
Reduced blood loss may minimize the need for repeated suctioning and improve visualization of anatomical structures, potentially contributing to shorter operative duration. However, surgical duration is also influenced by disease severity, surgical complexity, anatomical variations, and surgeon experience. Therefore, differences in operative time should be interpreted in the context of these additional factors.
Achievement of Target MAP and Supplementary Hypotensive Medication
The target MAP was achieved in 46 patients (92.0%) receiving dexmedetomidine compared with 42 patients (84.0%) receiving esmolol. Although the proportion was higher in the dexmedetomidine group, the difference was not statistically significant (p = 0.218). The mean time required to achieve the target MAP was shorter with dexmedetomidine (12.8 ± 3.6 versus 16.4 ± 4.2 minutes; p < 0.001).
Supplementary hypotensive medication was required in 4 patients (8.0%) in the dexmedetomidine group and 9 patients (18.0%) in the esmolol group, although the difference was not statistically significant (p = 0.137). These observations suggest that dexmedetomidine may facilitate earlier achievement of the desired haemodynamic target, with a lower numerical requirement for additional hypotensive agents.
Bajwa et al. [2] demonstrated the usefulness of both agents for controlled hypotension during FESS. The time required to achieve target MAP and the need for supplementary medication provide additional measures of haemodynamic control, although these outcomes should be interpreted alongside the duration of maintained target pressure and any episodes of excessive hypotension.
Postoperative Recovery Characteristics
Postoperative recovery was slower in the dexmedetomidine group, with longer times to eye opening and extubation. Mean time to eye opening was 9.8 ± 2.6 minutes in Group D compared with 7.2 ± 2.1 minutes in Group E (p < 0.001), while mean extubation time was 11.6 ± 3.1 versus 8.4 ± 2.5 minutes, respectively (p < 0.001). The mean duration of stay in the post-anaesthesia care unit was also longer in the dexmedetomidine group (52.4 ± 12.6 versus 46.8 ± 11.4 minutes; p = 0.022).
These differences may be explained by the sedative properties of dexmedetomidine, which can persist into the postoperative period. In contrast, esmolol has a short elimination half-life and lacks intrinsic sedative activity, potentially allowing more rapid emergence from anaesthesia. Omara et al. [4] also investigated postoperative recovery and sedation-related outcomes associated with these agents during endoscopic sinus surgery.
Although delayed emergence and extubation may be disadvantages when rapid recovery is required, the clinical relevance of these differences should be considered alongside postoperative haemodynamic stability, analgesic requirements, and recovery-room discharge criteria.
Postoperative Analgesia and Rescue Analgesic Requirements
Postoperative pain scores were lower in the dexmedetomidine group at all assessment intervals. At 30 minutes, mean pain scores were 2.4 ± 0.9 in Group D compared with 3.6 ± 1.1 in Group E (p < 0.001). Similar differences were observed at 1 hour (2.7 ± 1.0 versus 3.8 ± 1.2) and 2 hours (2.3 ± 0.9 versus 3.2 ± 1.1), with p < 0.001 at both intervals.
Rescue analgesia was required in 14 patients (28.0%) receiving dexmedetomidine compared with 27 patients (54.0%) receiving esmolol (p = 0.008). The mean time to first rescue analgesia was longer in the dexmedetomidine group (148.6 ± 34.2 versus 112.4 ± 29.6 minutes; p < 0.001).
These findings are consistent with the analgesic and analgesic-sparing properties of dexmedetomidine, mediated through central alpha-2 adrenergic receptor activation and modulation of nociceptive transmission. Omara et al. [4] investigated postoperative analgesia following dexmedetomidine and esmolol administration, while Bafna et al. [6] evaluated the analgesic effects of dexmedetomidine compared with clonidine.
The lower postoperative pain scores and reduced rescue analgesic requirements suggest a potential additional advantage of dexmedetomidine beyond intraoperative haemodynamic control. However, postoperative pain assessment may be influenced by residual sedation, background analgesia, and individual pain perception, which should be considered when interpreting these findings.
Perioperative Adverse Events and Safety
Perioperative adverse events were observed in both treatment groups, with no statistically significant differences in individual complications. Bradycardia occurred in 6 patients (12.0%) receiving dexmedetomidine compared with 3 patients (6.0%) receiving esmolol (p = 0.487). Hypotension below the target MAP was observed in 5 patients (10.0%) and 3 patients (6.0%), respectively (p = 0.715). Excessive postoperative sedation was numerically more frequent with dexmedetomidine (12.0% versus 4.0%; p = 0.269).
In contrast, tachycardia occurred in 4.0% of patients receiving dexmedetomidine compared with 12.0% receiving esmolol, while hypertension during emergence was observed in 4.0% and 10.0%, respectively. Postoperative nausea and vomiting were also numerically less frequent in the dexmedetomidine group, although these differences were not statistically significant.
These findings reflect the differing pharmacological properties of the two agents. The relatively higher frequency of bradycardia and excessive postoperative sedation with dexmedetomidine may be related to its central sympatholytic and sedative effects, whereas esmolol's short duration of action may provide less sustained attenuation of sympathetic responses during emergence. Previous studies by Shams et al. [1], Bajwa et al. [2], Sahu et al. [3], and Omara et al. [4] have also examined the haemodynamic safety and perioperative adverse effects of these agents.
Although no statistically significant differences were identified in individual adverse events, these findings should not be interpreted as evidence of equivalent safety, particularly given the sample size of 50 patients per group. Appropriate patient selection, careful dose titration, and continuous haemodynamic monitoring remain essential when using either agent for controlled hypotension.
Taken together, the comparative findings suggest that dexmedetomidine may offer advantages over esmolol in improving surgical-field visibility, reducing intraoperative blood loss, shortening surgical duration, and decreasing postoperative analgesic requirements during FESS. However, these potential benefits should be balanced against delayed postoperative recovery and the possibility of drug-related adverse effects. Selection of the hypotensive agent should therefore be individualized according to patient characteristics, cardiovascular status, anticipated surgical requirements, and postoperative recovery priorities.
CONCLUSION
Dexmedetomidine and esmolol are effective pharmacological options for controlled hypotension during functional endoscopic sinus surgery (FESS). The comparative findings suggest that dexmedetomidine may provide better surgical-field visibility, reduced intraoperative blood loss, shorter surgical duration, improved haemodynamic control, and lower postoperative analgesic requirements compared with esmolol. However, these advantages may be accompanied by prolonged emergence and postoperative recovery, along with an increased tendency towards bradycardia and sedation. Esmolol remains a useful alternative because of its rapid onset, short duration of action, and ease of titration, particularly when early postoperative recovery is desirable. The choice of hypotensive agent should therefore be individualized according to patient characteristics, surgical requirements, haemodynamic stability, and perioperative safety considerations.
Recommendations
1. Dexmedetomidine may be considered for controlled hypotension during FESS when improved surgical-field visibility, reduced intraoperative bleeding, and postoperative analgesia are important clinical priorities.
2. Esmolol may be preferred when rapid haemodynamic titration and early postoperative recovery are particularly desirable.
3. Continuous monitoring of haemodynamic parameters, including heart rate, blood pressure, and oxygen saturation, is essential to ensure adequate organ perfusion and promptly identify adverse events.
4. Selection of the hypotensive agent should consider baseline cardiovascular status, associated comorbidities, surgical complexity, anticipated operative duration, and individual patient characteristics.
5. Further multicentre randomized controlled trials with larger sample sizes, standardized anaesthetic protocols, and longer postoperative follow-up are recommended to establish the comparative efficacy and safety of these agents.
Strengths of the Study
The comparative framework incorporated 100 patients, with equal representation in the dexmedetomidine and esmolol groups. A major strength was the comprehensive evaluation of clinically relevant intraoperative and postoperative outcomes, including haemodynamic parameters, surgical-field visibility, estimated blood loss, surgical duration, postoperative pain, analgesic requirements, recovery characteristics, and perioperative adverse events. The use of the standardized Fromme–Boezaart grading scale and serial haemodynamic assessments provided a structured approach to evaluating surgical conditions and cardiovascular responses. Furthermore, the assessment of postoperative recovery and analgesic requirements alongside intraoperative outcomes allowed a broader comparison of the potential benefits and disadvantages of the two agents.
Limitations of the Study
The principal limitations included the single-centre setting and relatively modest sample size, which may restrict generalizability and the ability to detect uncommon perioperative adverse events. Inclusion of only patients with American Society of Anesthesiologists (ASA) physical status I and II limits applicability to patients with significant systemic comorbidities. Surgical-field grading involves a degree of subjective assessment and may be influenced by disease severity, anatomical variations, surgical complexity, and surgeon-related factors. Variations in background anaesthesia and perioperative medications may also affect haemodynamic responses and postoperative recovery. Additionally, the limited postoperative observation period restricts assessment of delayed complications. Larger multicentre investigations with standardized protocols and extended follow-up are warranted.
REFERENCES
1. Shams T, El Bahnasawe NS, Abu-Samra M, El-Masry R. Induced hypotension for functional endoscopic sinus surgery: a comparative study of dexmedetomidine versus esmolol. Saudi J Anaesth. 2013;7(2):175–180. doi: 10.4103/1658-354X.114073. PMID: 23956719.
2. Bajwa SJS, Kaur J, Kulshrestha A, Haldar R, Sethi R, Singh A. Nitroglycerine, esmolol and dexmedetomidine for induced hypotension during functional endoscopic sinus surgery: a comparative evaluation. J Anaesthesiol Clin Pharmacol. 2016;32(2):192–197. doi: 10.4103/0970-9185.173325. PMID: 27275048.
3. Sahu BP, Nayak LK, Mohapatra PS, Mishra K. Induced hypotension in functional endoscopic sinus surgery: a comparative study of dexmedetomidine and esmolol. Cureus. 2021;13(5):e15069. doi: 10.7759/cureus.15069. PMID: 34150405.
4. Omara AF, Mohammed Abo Hagar A, Fawzy Amer A. The effect of esmolol versus dexmedetomidine on postoperative pain control in endoscopic sinus surgery: a randomized trial. Anesth Pain Med. 2025;15(3):e158065. doi: 10.5812/aapm-158065. PMID: 40727636.
5. Srivastava U, Dupargude AB, Kumar D, Joshi K, Gupta A. Controlled hypotension for functional endoscopic sinus surgery: comparison of esmolol and nitroglycerine. Indian J Otolaryngol Head Neck Surg. 2013;65(Suppl 2):440–444. doi: 10.1007/s12070-013-0655-5. PMID: 24427694.
6. Bafna U, Sharma P, Singhal RK, Gurjar SS, Bhargava SK. Comparison of hypotensive properties of dexmedetomidine versus clonidine for induced hypotension during functional endoscopic sinus surgery: a randomised, double-blind interventional study. Indian J Anaesth. 2021;65(8):579–585. doi: 10.4103/ija.IJA_57_21. PMID: 34584280.
7. Gupta KK, Kumari V, Kaur S, Singh A. Comparative evaluation of propofol versus dexmedetomidine infusion for hypotensive anesthesia during functional endoscopic sinus surgery: a prospective randomized trial. Anesth Pain Med (Seoul). 2022;17(3):271–279. doi: 10.17085/apm.21118. PMID: 35918859.
8. Escamilla Y, Cardesín A, Samara L, López S, Izquierdo A, Fradera M, et al. Randomized clinical trial to compare the efficacy to improve the quality of surgical field of hypotensive anesthesia with clonidine or dexmedetomidine during functional endoscopic sinus surgery. Eur Arch Otorhinolaryngol. 2019;276(11):3095–3104. doi: 10.1007/s00405-019-05575-6. PMID: 31363901.
Recommended Articles
Original Article
Spirometry as a tool for assessing asthma control in children on follow up
Correlation Between EGFR Mutation Subtypes and Histopathological Features in Predicting Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review